Investors are increasingly gravitating towards dividend stocks in 2026, drawn by their potential for steady income and perceived stability. Bristol Myers Squibb (BMY) stands out with a 4.4% yield, significantly higher than the S&P 500 average of 1.2%. However, looming patent expirations for key drugs like Eliquis and Opdivo raise concerns about the company’s future earnings and cash flow, which are critical for sustaining its dividend payments.
While Bristol Myers has a strong history of dividend increases, the current uncertainty surrounding its financial outlook makes it a risky choice for income-focused investors. The company’s revenue has stagnated, and forecasts suggest a decline this year, prompting questions about its ability to maintain its dividend amid potential cash flow pressures and the need for acquisitions.
For market professionals, the key takeaway is to approach Bristol Myers with caution. Given the uncertainties, diversifying into dividend-paying index funds may provide a more reliable income stream without the volatility associated with individual stocks like BMY.
Source: fool.com